Additional file 1: Description of Excluded RCTs
Excluded
Patient
Numbe Interventi
Trial
Inclusion
r of
Control
on
Follow
Outcomes
Reason
Up
for
Pts /
Duratio
Exclusio
Centre
n
n
s
Post CABG
Saw 2015
Elective
70 /
Ticagrelor
ASA 81
12
Graft
-
[29]
CABG
single
90 bid +
mg/d
months
patency;
Published
ASA 81
adverse
only as
mg/d
cardiovascul conferenc
ar events;
e abstract
bleeding
with no
reported
outcome
events
Thopte
Elective
74 /
Clopidogre
ASA 150
3
Graft
-
2014 [30]
CABG
single
l 75 + ASA
mg/d
months
patency;
Published
adverse
only as
150 mg/d
cardiovascul conferenc
ar events;
e abstract
bleeding
with no
reported
outcome
events
Wang
Off Pump
60 /
Clopidogre
ASA 100
Hospital
Platelet
-No
2013 [28,
CABG
single
l 75 + ASA
mg/d
dischar
aggregation
reported
ge
assays
events
13d
“Cardiac
-Only
post op)
events”
short
(myocardial
term
infarction,
interventi
31]
100 mg/d
(mean
heart failure, on and
death);
follow up
bleeding
Gao 2009
Elective
197 /
Clopidogre
Clopidogr
12
Graft
-No
[24]
CABG
single
l 75 mg/d
el 75
months
patency;
mortality,
+ ASA 100
mg/d
mortality;
bleeding
bleeding
or other
mg/d
clinical
events
Mujanovic
Elective
20 /
Clopidogre
ASA 100
3
Graft
-No
200 [26]
Off Pump
single
l 150 then
mg/d
months
patency;
reported
75 mg/d +
mortality;
events
ASA 100
bleeding.
CABG
mg/d
Kayaciogl
Elective
40 /
Clopidogre
ASA 300
6
Graft
-No
u 2008
CABG
single
l 75 mg/d
mg/d
months
patency by
reported
[25]
with
+ ASA 300
cath in
clinical
platelets
mg/d
those with
events
positive
(7/20
stress tests
ASA only
>450
patients
had
positive
stress
test tests
and 5/7
had new
stenoses)
vs 0/20
clopidogr
el + ASA
Nielsen
Elective
29 /
Clopidogre
ASA 150
2
Thrombo-
-No
2007 [27]
Off Pump
single
l 75 mg/d x
mg/d
months
elasto-
reported
30d + ASA
graphy and
clinical
150 mg/d
platelet
events
CABG
inhibition
studies;
clinical
outcomes
Suwalski
Elective
50 /
Clopidogre
ASA 150
6
Mortality,
-Single
2012 [34]
Off Pump
single
l 75 mg/d
mg/d
months
revasc,
anti-
stroke,
platelet
bleeding
therapy
CABG
-Abstract
only
Tetik
Elective
50 /
Clopidogre
ASA 300
6
Platelet
-Single
2010 [35]
CABG
single
l 75 mg/d
mg/d
months
aggregation
anti-
assays,
platelet
mortality,
CV events,
therapy
bleeding
Lim 2004
Elective
54 /
Clopidogre
ASA 100
[33, 36,
CABG
single
l 75 mg/d
or 325
37]
5 days
Platelet
-Single
aggregation
anti-
mg/d (2
platelet
groups)
therapy
David
Elective
62 /
Clopidogre
Ticlopidin
1999 [32]
CABG
single
l 50, 75, or
100 mg/d
28 days
Bleeding
-Single
e 250 mg
time and
anti-
bid
platelet
platelet
aggregation
therapy
(3 groups)
Rafiq
Hypercoa
(250) /
Clopidogre
ASA 75
3
Ongoing
2012 [48]
g-ulable
single
l 75 ng/d +
mg/d
months
NCT
Elective
ASA 75
CABG
mg/d
01046942
Acute Coronary Syndrome Requiring CABG
CURREN
ACS w/
25,086
Clopidogre
Clopidogr
T-OASIS
EKG or
/
l 600 then
el 300
7 2010
enzymes
multipl
150 mg/d x then 75
[44]
planned
e
6d then 75
mg/d
interventi
PCI
(CABG
mg/d (also
(also
on and
n=~200 300-325 vs 300-325
0 [8%])
30 days
Mortality,
-Only
MI, stroke,
short
bleeding
term
follow up
75-100
vs 75-
mg/d ASA
100 mg/d
-no post
random-
ASA
CABG
ization)
random-
interventi
ization)
on
-no
separate
data for
CABG
subgroup
JUMBO-
Elective
904 /
Prasugrel
Clopidogr
TIMI 26
or urgent
80
40-60 then
2005;
PCI
30 days
Bleeding,
-Only
el 300
mortality,
short
7.5-15
then 75
MI, stroke
term
Phase 2
mg/d +
mg/d +
interventi
[42]
ASA
ASA
on and
follow up
-no
separate
data for
CABG
subgroup
DISPERS
NSTE-
990 /
Ticagrelor
Clopidogr
12
Bleeding,
-no
E-2 2007;
ACS
152
90-180 mg
el 300
weeks
mortality,
separate
Phase 2
(CABG
bid + ASA
then 75
MI, stroke
data for
[39]
n=84)
Prior
CABG
ASA
subgroup
1133
Ticagrelor
Clopidogr
360
Mortality,
-no
CABG
(of
180 then
el 300-
days
MI, stroke,
CABG
(median
18,613) 90 mg bid
600 then
bleeding
during
9y) 2013,
/ 862
75 mg/d
study
+ ASA
period
PLATO
Substudy
[46]
ACS
mg/d +
+ ASA
Prior
Recent
1480
Clopidogre
ASA 325
1.6
Mortality,
-Only
CABG
MI or
(of
l 75 mg/d
mg/d
years
MI, stroke,
single
2001,
CVA, or
19,185)
(mean)
bleeding
anti-
CAPRIE
PVD
/ 384
platelet
Substudy
therapy
[45]
-no
CABG
during
study
period
TRILOGY
ACS
9326 /
Prasugrel
Clopidogr
14.8
Mortality,
-no
ACS 2012
without
multipl
30 then 5-
el 300
months
MI, stroke,
separate
[41]
planned
e
10 mg/d +
then 75
(median
bleeding
data for
ASA
mg/d +
)
revasc.
CABG
ASA
subgroup
CHARISM
CV
15,603
Clopidogre
ASA 75-
28
Mortality,
-no
A 2006
disease
/ 768
l 75 mg/d
162 mg/d
months
MI, stroke,
separate
[38]
or
+ ASA 75-
(median
bleeding
data for
multiple
162 mg/d
)
CABG
risk
subgroup
factors
CABG
STEMI
136
Clopidogre
ASA 150-
Subgroup
treated
(3491)
l 300 then
325 then
30 days
Mortality,
-median
MI, stroke,
clopidogr
with
CLARITYTIMI 28
/ 319
75 mg/d +
75-162
fibrinolysi
ASA 150-
mg/d
s
325 then
4d (prior
75-162
to
mg/d
CABG);
2007 [43]
bleeding
el
treatment
only
8/136
patients
resumed
post
CABG
COMMIT
AMI (93%
45,852
Clopidogre
ASA 162
2005 [40]
STEMI)
/ 1250
l 75 mg/d
mg/d
without
+ ASA 162
planned
mg/d
28 days
Mortality,
-no
MI, stroke,
separate
bleeding
data for
CABG
PCI
subgroup
TRACER
NSTE-
1312
2012 [47]
ACS
(12,944 (PAR-1
) / 818
Voraxapar
antagonist)
Clopidogr
el + ASA
1 year
Mortality,
-triple
MI, stroke,
anti-
bleeding
platelet
+
therapy
clopidogrel
with non-
+ ASA
P2Y12
antagonis
t